Tonix Pharmaceuticals Holding Corp. announced the presentation of additional safety and tolerability data from RESILIENT, the second positive Phase III study evaluating TNX 102 SL (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia, at Biotech Showcase 2024 in San Francisco, January 8-10
Tonix Pharmaceuticals Holding Corp. announced that it is eliminating the interim analyses in its registration-enabling, confirmatory Phase III RESILIENT study of TNX 102 SL for fibromyalgia and its Phase II PREVENTION study of TNX 1900 for chronic migraine
TNX 102 SL from Tonix Pharmaceuticals met its pre-specified primary endpoint in the Phase III RELIEF trial, significantly reducing daily pain compared to placebo (p=0.01) in participants with fibromyalgia
The original European League Against Rheumatism recommendations for managing fibromyalgia assessed evidence up to 2005. The paucity of studies meant that most recommendations were ‘expert opinion’.
Top-line results were announced by Pfizer of a double-blind, Phase III study evaluating pregabalin controlled-release (CR) formulation in patients with...
Tonix Pharmaceuticals Holding Corp.is currently focused on preparing a New Drug Application (NDA) for Tonmya (formerly TNX-102 SL, sublingual cyclobenzaprine HCl) for the management of fibromyalgia, announced the online publication of a research paper in the Journal Pain
Abbott has announced the FDA approved the Masters HP 15mm rotatable mechanical heart valve, the world's smallest mechanical heart valve,...
Tonix Pharmaceuticals Holding Corp. announced that previously disclosed results from the Phase III RELIEF study of TNX 102 SL for the management of fibromyalgia have been published in the peer-reviewed journal Arthritis Care & Research, an official journal of the American College of Rheumatology
RedHill Biopharma has announced that the positive final results, announced in June 2015, of the first Phase III study with...